Method for purifying blood plasma against pathological protein components in burnt patients

FIELD: medicine.

SUBSTANCE: the present innovation deals with ways for purifying blood plasma in burnt patients followed by applying the plasma obtained either while carrying out the next plasmapheresis or as independent transfusion medium. For this purpose, it is necessary to carry out plasmapheresis in burnt patients. Heparin should be added into plasma removed during plasmapheresis and, additionally, hemodesis, followed by incubation at +4° C for about 5-18 h, then it should be centrifuged for depositing cryoprecipitate. The innovation suggested enables to alter conditions of cryoprecipitation so, that it is possible to increase precipitation of fibrinogen and fibrin-monomeric complexes, the quantity of which is sharply observed in burnt patients.

EFFECT: higher efficiency of purification.

1 tbl

 

The present invention relates to medicine, in particular to methods of treatment of burn disease with marked disorders of microcirculation and hemostasis.

Sharp activation of hemostasis occurs from the first hours after severe thermal injury, continues throughout the acute period of burn disease and determines the development of microcirculation disorders, thrombotic and hemorrhagic complications.

It is known that violations of rheological properties of blood and its activation of intravascular coagulation is largely associated with hyperfibrinogenemia, which not only increases the viscosity of blood plasma, but also stimulates the aggregation of red blood cells and platelets. In particular, increasing the concentration of fibrinogen in the blood is considered as a marker of high risk of myocardial infarction.

The level of soluble fibrin-monomer complexes (; fibrin monomer complex) in the blood increases when the hypercoagulability of various origins and plays a major role in the development of thrombotic complications.

Therefore, the removal from plasma fibrinogen; fibrin monomer complex and is an essential component of treatment of disorders of hemostasis and microcirculation in many pathological conditions, particularly in burn disease.

Closest to the proposed technical solution is the method of purification of blood plasma from pathological Belko what's complexes, described in the copyright certificate №1181668 Haerbaling, Ugusawnh, Saucily and others, published in Gazette No. 36 "Opening. Invention." in 1985, This method lies in the fact that in remote plasmapheresis plasma add heparin based 7-10 thousand IU/l, incubated at +4-6°for 5-18 hours, separating the precipitate (cryoprecipitate) by centrifugation and the resulting supernatant is frozen at a temperature of from -20°-35°With subsequent thawing, by centrifugation and used as a replacement solution plasmapheresis.

However, despite the fact that using heprincipalreci possible to reduce the amount of fibrinogen; fibrin monomer complex and in plasma, eksponirovannoi plasmapheresis, this reduction is small, so the transfusion modified in this way plasma has expressed no influence on the content of fibrinogen; fibrin monomer complex and in the blood plasma of the patient. The possibility of enhancing deposition of these components when cryoprecipitate is important.

The task of the invention to increase the degree of deposition of fibrinogen; fibrin monomer complex and in the blood plasma of burn patients when it heprincipalreci.

This problem is solved due to the fact that they use the blood plasma of burn patients, in which before incubation further what about the add gemodez.

The method is as follows: the patient with burn disease perform plasmapheresis in a remote plasma type of heparin-based 7-10 thousand IU/l and gemodez in the ratio of 1 part gemodeza into 4 parts plasma, incubated plasma at +4-6°for 5-18 hours, separating the precipitate (cryoprecipitate) by centrifugation mode 3500 rpm at +4°C for 20 min and the resulting supernatant with reduced levels of fibrinogen; fibrin monomer complex and frozen at a temperature of from -20°C to -35°With subsequent thawing, by centrifugation and used as a replacement solution for the next plasmapheresis or as a separate transfusion environment.

The table shows the comparative rate of deposition of fibrinogen; fibrin monomer complex and expressed in percent by heprincipalreci blood plasma, remote in plasmapheresis in patients with burns, using gemodeza without it.

IndexCryoprecipitate using gemodezaCryoprecipitate without using gemodeza
; Fibrin monomer complex74,4±4,9936,6±5,27
Fibrinogen42,7±10,3425,0±4,36

The floor is i.i.d. data testify, using gemodeza if heprincipalreci plasma dramatically increases the degree of deposition and fibrinogen; fibrin monomer complex.

This method can be used in the treatment of many pathological conditions involving hyperfibrinogenemia, increase in blood; fibrin monomer complex, activation of the aggregation of blood cells (ischemic heart disease, diabetic foot syndrome, purulent surgical diseases, and others).

The method is simple, cheap, does not require expensive equipment and are available for any clinic thermal lesions.

The method of purification of blood plasma from pathological protein components by performing plasmapheresis, add in remote plasmapheresis plasma heparin incubation at a temperature of +4°for 5-18 h and centrifugation to precipitate cryoprecipitate, characterized in that use blood plasma of burn patients, in which to enhance cryoprecipitate fibrinogen and fibrinogenic complexes before incubation additionally add gemodez.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves making surgical intervention after Widman with patient blood taken in the amount of 10-20 ml before placing flap. The blood is centrifuged during 11-13 min at 2400-2800 rpm and divided into 3 fractions like erythrocytes, plasma of high blood platelets content and plasma of low blood platelets content as a result of the treatment. The plasma of high blood platelets content is taken from laboratory glass and mixed with beta-tribasic calcium phosphate powder in proportion of 1:3. Then, the produced mixture is placed into defect zone and the flaps are fixed with sutures.

EFFECT: no additional surgical intervention needed; excluded allergic responses.

FIELD: medicine, surgery.

SUBSTANCE: method involves using dimexide 100% solution in 2% Novocain taken in the ratio 1:1 that is used as a compress for 30 min. Invention promotes to enhancing the effectiveness of preoperational treatment in simultaneous effect on pain endings. Invention can be used in carrying out preoperational treatment of skin.

EFFECT: improved treatment method.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with preventing hemodynamic complications at restoring circulation in a prolongly ischemized limb, or due to premeditated tourniquet application during operative interference. For this purpose, 5-12 min before the onset of circulatory restoration it is necessary to start intravenous injection of antihistamine and glucocorticosteroid preparations, followed by drop-by-drop infusion of inhibitors of proteolytic enzymes which should be continued after tourniquet removal, as well. The method provides tourniquet shock and tourniquet shock-associated complications along with developing the chance for increasing the duration period of operation.

EFFECT: higher efficiency of prophylaxis.

3 ex

FIELD: medicine, proctology.

SUBSTANCE: the present innovation deals with introducing a sclerosing preparation consisting of equal parts of 96% alcohol and 2% lidocain at the quantity of 2-4 ml, for all fissures it is necessary to inject 10 ml 0.5%-novocain solution and 2 ml solcoseryl or actovegin, then one should change the direction to move a needle towards coccyx towards sphincter's external diameter to introduce 5 ml 0.5%-Novocain solution and, not shifting a needle, one should introduce a sclerosing preparation. The innovation enables to conduct simultaneously the following procedures: anesthesia, the rupture of adhesions, blocking painful and sensitive branches of pudendal nerve that innervate ulcerous area that leads then to decreased pain syndrome, decreased sphincter's spasm and better ulcer's healing.

EFFECT: higher efficiency of sclerotherapy.

2 dwg, 2 ex

FIELD: medicine, surgery.

SUBSTANCE: the present innovation deals with treating patients in early post-operational period after interferences in mediastinal and esophageal organs. One should conduct the course of subxyphoidal bolus injection of lymph-stimulating mixture containing 64 U lidase diluted in 1 ml 5%-glucose, 25 mg suspension of hydrocortisone followed by slow drop-by-drop injection of 500 mg metrogil during the first 3 d of post-operational period. The innovation provides high concentration of curative preparations in operation region at decreasing their dosages, decreased toxic effects and risk of purulent-inflammatory complications due to stimulating drainage-detoxication function of lymph system.

EFFECT: higher efficiency.

1 ex

FIELD: medicine.

SUBSTANCE: the present innovation should be fulfilled due to performing sclerotherapy with 96%-ethanol under ultrasound control at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasms and 3-5 ml in case of cystic neoplasm after liquid aspiration. Moreover, a day before each course of sclerotherapy one should introduce Movalis for 5-10 d once daily after meals. The course of sclerotherapy should be started with introducing 96%-ethanol, then 8-10 d later it is necessary to introduce benzyl peniccilin sodium salt at the dosage of 0.5-1 ml/ml of nodal volume in case of nodal neoplasm, and 0.5 ml after liquid aspiration - in case of cystic neoplasm. The innovation enables to decrease side manifestations of complex therapy performed due to decreasing the quantity of injections.

EFFECT: higher efficiency of therapy.

1 cl, 4 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a hemostatic film onto damaged spleen, moreover, as hemostatic material one should apply hyaluronic acid-based film (HA) being chemically associated with 5-aminosalicylic acid and impregnated with ferrum of the following total structural formula:

. Moreover, substitution degree of carboxylic groups with 5-aminosalicylic acid corresponds to 30-50% M. The innovation provides stimulation of fibroblastic activity and accelerated formation of granulations.

EFFECT: higher efficiency of therapy.

8 dwg

FIELD: medicine, surgery.

SUBSTANCE: method involves using chlorhexidine aqueous solution saturated with carbon dioxide by bubbling that is fed into wound with simultaneous evacuation its from wound with wound secret. Sanitation is carried out by two séances per 24 h for 10-20 min. Invention promotes to mechanical cleaning wound surface, effective bacterial decontamination, improving proliferative processes that, in turn, promotes to rapid wound healing. Invention can be used for treatment of suppurative-inflammatory processes in closed cavities and wound infections.

EFFECT: improved treatment method.

3 cl

FIELD: medicine, surgery.

SUBSTANCE: on should perform continuous washing patient's foot for several days due to placing it into hermetically sealed reservoir with antiseptic followed by vacuum evaporation at rarefaction being 0.2-0.4 kgf/sq. cm, moreover, procedures should be alternated at periodicity of 3-4 h. The present innovation enables to accelerate wound purification and increase regenerative activity of plantar tissues due to suppressing activity of the agent of purulent-necrotic process, activation of local immunity of affected tissues and restoration of microcirculation and oxygenation of these tissues.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, abdominal surgery.

SUBSTANCE: after performing operative interference and sanitation of patient's abdominal cavity the latter should be introduced with sterile phosphate-citrate buffer solution at pH being5.6 at the quantity of 1 l to be applied for washing the organs of abdominal cavity. Then its greater part should be removed by keeping up to 200 ml solution in abdominal cavity. The present innovation enables to activate thrombin being a constituent of an exudates in abdominal cavity and inhibits the development of adhesion's primary component - fibrin.

EFFECT: higher efficiency of prophylaxis.

1 ex

FIELD: medicine.

SUBSTANCE: method involves administering combined sanatorium-and-spa treatment after patient acclimatization on low altitude mountain resort takes place. The treatment comprises mineral carbonic acid water baths physical training exercises on terraincour according to generally applied methods and plasmapheresis procedures. Hypercholesterolemia of 5,0-6.5 mmole/l being the case or cholesterol level being higher than target value of 3.6 mmole/l, it is enough to give 3-4 procedures with exfusion to 1-1.5 times circulating plasma volume. Total cholesterol level being from 6.5 to 7.8 mmole/l, plasma exfusion volume is equal to 1.5-2 times circulating plasma volume. Hypercholesterolemia being higher than 7.8 mmole/l, plasma exfusion volume is equal to 2-2.5 times circulating plasma volume.

EFFECT: enhanced effectiveness of treatment.

1 dwg, 3 tbl

FIELD: medicine, obstetrics.

SUBSTANCE: at the first stage of pregravidic training one should introduce leukinferon per 10000 IU intramuscularly every other day 10 times, at the second stage it is necessary to perform 3 seances of discrete plasmapheresis. The present innovation enables to decrease the frequency in developing gestosis and the risk for abortion due to normalized activity of female immune system, that in its turn, enables to stop virusemia and virusuria, prevent fetoplacental failure and intrauterine fetal infectioning.

EFFECT: higher efficiency of training.

3 ex, 1 tbl

FIELD: medicine, anesthesiology-resuscitation, infectology, detoxication.

SUBSTANCE: the innovation suggested interrupts infectious-toxic shock, moreover, after that it is necessary to prescribe peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg. Then one should sample patient's blood to obtain leukocytes to be washed and diluted in 0.9%-NaCl solution, activated due to incubation with immunophan and intravenously injected for a patient. Then comes peroral intake of Reaferon-EC-Lipint at the dosage of 10000 - 15000 U/kg once daily for 5 d. The innovation enables to decrease the number of complications and lethality due to decreasing immunodeficiency.

EFFECT: higher efficiency of therapy.

3 ex, 1 tbl

FIELD: medicine, endocrinology.

SUBSTANCE: one should introduce heparin into plasma separated during plasmapheresis at 9000-11000 U/l plasma to incubate it at 4-6 C for 12 h, not less, separate precipitate due to plasma centrifuging at 7-9 C for 15-25 min and introduce the rest plasma into patient's blood. Such procedures should be carried out every other day 5-7 times. The present innovation enables to decrease glomerulosclerosis progressing, avoid excessive heparinization and heparinization-associated complications and, also, those associated with introduction of donor's plasma.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: method involves using apparatus supporting washed erythrocyte reinfusion as far as the erythrocytes become available. Reinfusion duration is limited with 3-4 h of the nearest postoperative period. The device has valve for preventing excessive rarefaction to occur. The valve is connected to main pipe for taking blood via T-shaped connector. The valve has membrane member which inlet flow nipple is connected to valve nozzle, shutter and upper and lower strap springs connected to each other. Screw for setting zero on the upper strap providing membrane member displacement. Adjusting screw is mounted on the lower strap allowing detaching shutter from the nozzle to make communication to atmosphere.

EFFECT: enhanced effectiveness in compensating postoperative blood losses with full-valued formed blood elements.

2 cl, 2 dwg

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

The invention relates to medicine, namely to oral surgery, and can be used in the surgical treatment of chronic periodontitis
The invention relates to medicine, endocrinology

The invention relates to medicine, urology, and can be used for the treatment of autoimmune infertility
The invention relates to medicine, in particular to urology and andrology, and can be used in the treatment of autoimmune infertility in men

FIELD: medicine.

SUBSTANCE: method involves introducing means containing heavy elements into tumor and expose it to X-ray radiation. A heavy chemical element having number of 53, 55-83 is used. The means contains one or several of said elements with additional ligand introduced as iminodiacetic acid or its derivatives or crownethers or porphyrins and a water-soluble polymer. The means is introduced in systemic or direct way into tumor with following X-ray irradiation of power of 10-200 keV being applied.

EFFECT: increased photon therapy dose concentrated in tumor tissue with concurrently reduced radiation exposure upon the unaffected tissues.

4 cl, 4 dwg, 6 tbl

Up!